{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:02:00Z","timestamp":1790712120419,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Sun Pharma"},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012331","name":"Leo Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.anai.2019.01.016","type":"journal-article","created":{"date-parts":[[2019,1,27]],"date-time":"2019-01-27T02:23:02Z","timestamp":1548555782000},"page":"158-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":44,"title":["Chronic itch management: therapies beyond those targeting the immune system"],"prefix":"10.1016","volume":"123","author":[{"given":"Emilie","family":"Fowler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil","family":"Yosipovitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"17","key":"10.1016\/j.anai.2019.01.016_bib1","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJMcp1208814","article-title":"Chronic pruritus","volume":"368","author":"Yosipovitch","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.anai.2019.01.016_bib2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.clindermatol.2011.11.004","article-title":"Psychosomatic factors in pruritus","volume":"31","author":"Tey","year":"2013","journal-title":"Clin Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib3","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jaci.2018.09.005","article-title":"Itch: from mechanism to (novel) therapeutic approaches","volume":"142","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2019.01.016_bib4","doi-asserted-by":"crossref","DOI":"10.1097\/j.pain.0000000000001220","article-title":"Alloknesis and hyperknesis: mechanisms, assessment methodology, and clinical implications of itch sensitization","volume":"159","author":"Andersen","year":"2018","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib5","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.neuron.2015.11.001","article-title":"G\u00a0protein-coupled receptors: dynamic machines for signaling pain and itch","volume":"88","author":"Geppetti","year":"2015","journal-title":"Neuron"},{"key":"10.1016\/j.anai.2019.01.016_bib6","series-title":"Pharmacology of Itch","first-page":"339","article-title":"Current topical and systemic therapies for itch","author":"Leslie","year":"2015"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.det.2018.02.005","article-title":"Diagnosis and management of neuropathic itch","volume":"36","author":"Rosen","year":"2018","journal-title":"Dermatol Clin"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib8","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.sder.2011.04.008","article-title":"Topical therapies for pruritus","volume":"30","author":"Elmariah","year":"2011","journal-title":"Semin Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib9","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/09546630802441218","article-title":"A\u00a0pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients","volume":"20","author":"Young","year":"2009","journal-title":"J\u00a0Dermatol Treat"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2016.10.030","article-title":"Topical ketamine-amitriptyline-lidocaine for chronic pruritus: a retrospective study assessing efficacy and tolerability","volume":"76","author":"Lee","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.anai.2019.01.016_bib11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1517\/14656566.2010.481670","article-title":"Topical capsaicin: the fire of a \u2018hot\u2019 medicine is reignited","volume":"11","author":"Papoiu","year":"2010","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib12","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1067\/mjd.2001.110059","article-title":"Treatment of prurigo nodularis with topical capsaicin","volume":"44","author":"St\u00e4nder","year":"2001","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2019.01.016_bib13","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5021\/ad.2016.28.1.86","article-title":"Considerable variability in the efficacy of 8% capsaicin topical patches in the treatment of chronic pruritus in 3 patients with notalgia paresthetica","volume":"28","author":"Andersen","year":"2016","journal-title":"Ann Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib14","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1365-2133.2011.10501.x","article-title":"Treatment of notalgia paraesthetica with an 8% capsaicin patch","volume":"165","author":"Metz","year":"2011","journal-title":"Br J Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2019.01.016_bib15","first-page":"864","article-title":"Successful treatment of refractory neuropathic pruritus with capsaicin 8% patch: a bicentric retrospective study with long-term follow-up","volume":"95","author":"Misery","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib16","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1365-2133.2009.09628.x","article-title":"Ethnic differences in pain, itch and thermal detection in response to topical capsaicin: African Americans display a notably limited hyperalgesia and neurogenic inflammation","volume":"162","author":"Wang","year":"2010","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib17","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.jid.2017.12.025","article-title":"Cooling relief of acute and chronic itch requires TRPM8 channels and neurons","volume":"138","author":"Palkar","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib18","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.jaad.2007.04.008","article-title":"Menthol: a refreshing look at this ancient compound","volume":"57","author":"Patel","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib19","doi-asserted-by":"crossref","first-page":"520","DOI":"10.2340\/00015555-1564","article-title":"A\u00a0novel topical formulation containing strontium chloride signifcantly reduces the intensity and duration of cowhage-induced itch","volume":"93","author":"Papoiu","year":"2013","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1159\/000018367","article-title":"Strontium nitrate decreased histamine-induced itch magnitude and duration in man","volume":"200","author":"Zhai","year":"2000","journal-title":"Dermatology"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","article-title":"Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin","volume":"38","author":"St\u00e4nder","year":"2005","journal-title":"J\u00a0Dermatol Sci"},{"issue":"1","key":"10.1016\/j.anai.2019.01.016_bib22","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jaad.2017.02.056","article-title":"The role of cannabinoids in dermatology","volume":"77","author":"Mounessa","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/j.0007-0963.2004.05889.x","article-title":"Brachioradial pruritus: response to treatment with gabapentin","volume":"150","author":"Winhoven","year":"2004","journal-title":"Br J Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1365-2133.2010.09783.x","article-title":"Botulinum toxin type A for neuropathic itch","volume":"163","author":"Wallengren","year":"2010","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib25","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1365-2133.2011.10749.x","article-title":"Botulinum A toxin and brachioradial pruritus","volume":"166","author":"Kavanagh","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2019.01.016_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaad.2017.08.001","article-title":"Botulinum toxin type A for the treatment of localized recalcitrant chronic pruritus","volume":"78","author":"Boozalis","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jaad.2016.02.1237","article-title":"Gabapentin and pregabalin for the treatment of chronic pruritus","volume":"75","author":"Matsuda","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1590\/abd1806-4841.20142777","article-title":"Efficacy of gabapentin in the improvement of pruritus and quality of life of patients with notalgia paresthetica","volume":"89","author":"Maciel","year":"2014","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib29","first-page":"2007","article-title":"A\u00a0case of post-herpetic itch treated with gabapentin","volume":"56","author":"Kroshinsky","year":"2007","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.det.2018.02.003","article-title":"Prurigo nodularis and its management","volume":"36","author":"Zeidler","year":"2018","journal-title":"Dermatol Clin"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib31","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.jaad.2017.08.025","article-title":"Use of oral antidepressants in patients with chronic pruritus: A systematic review","volume":"77","author":"Kouwenhoven","year":"2017","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib32","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/1346-8138.12154","article-title":"Effective treatment of notalgia paresthetica with amitriptyline","volume":"40","author":"Yeo","year":"2013","journal-title":"J\u00a0Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib33","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1365-2230.2004.01642.x","article-title":"Brachioradial pruritus: an enigmatic entity","volume":"29","author":"Barry","year":"2004","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib34","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2018.05.027","article-title":"Dose escalation of doxepin for intractable pruritus","volume":"79","author":"Beck","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib35","first-page":"889","article-title":"Mirtazapine for reducing nocturnal itch in patients with chronic pruritus: a pilot study","volume":"50","author":"Hundley","year":"2004","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaad.2005.12.010","article-title":"Butorphanol for treatment of intractable pruritus","volume":"54","author":"Dawn","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.anai.2019.01.016_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/AJP.0000000000000211","article-title":"Nalbuphine for treatment of opioid-induced pruritus: a systematic review of literature","volume":"32","author":"Jannuzzi","year":"2016","journal-title":"Clin J Pain"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib38","doi-asserted-by":"crossref","first-page":"A65","DOI":"10.1053\/j.ajkd.2016.03.192","article-title":"Nalbuphine ER tablets in hemodialysis patients with severe uremic pruritus: multicenter, randomized, double-blind, placebo-controlled trial","volume":"67","author":"Kumar","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib40","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/ndt\/gfp588","article-title":"Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study","volume":"25","author":"Kumagai","year":"2010","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib42","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.jaad.2018.02.030","article-title":"Serlopitant for the treatment of chronic pruritus: results of a randomized, multicenter, placebo-controlled phase 2 clinical trial","volume":"78","author":"Yosipovitch","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib43","doi-asserted-by":"crossref","first-page":"AB300","DOI":"10.1016\/j.jaad.2018.05.1184","article-title":"Tradipitant improves worst itch and disease severity in patients with chronic pruritus related to atopic dermatitis","volume":"79","author":"Heitman","year":"2018","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.anai.2019.01.016_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.jaad.2009.08.052","article-title":"Antipruritic treatment with systemic \u03bc-opioid receptor antagonists: a review","volume":"63","author":"Phan","year":"2010","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1371\/journal.pone.0010968","article-title":"Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy","volume":"5","author":"St\u00e4nder","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.anai.2019.01.016_bib46","first-page":"665","article-title":"Oral aprepitant in the therapy of refractory pruritus in erythrodermic cutaneous T-cell lymphoma","volume":"164","author":"Booken","year":"2011","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib47","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1001\/jamadermatol.2013.170","article-title":"The use of aprepitant in brachioradial pruritus","volume":"149","author":"Ally","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib48","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jaad.2015.09.039","article-title":"Thalidomide for the treatment of chronic refractory pruritus","volume":"74","author":"Sharma","year":"2016","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"7","key":"10.1016\/j.anai.2019.01.016_bib49","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000187978","article-title":"Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial","volume":"67","author":"Silva","year":"1994","journal-title":"Nephron"},{"issue":"44","key":"10.1016\/j.anai.2019.01.016_bib51","doi-asserted-by":"crossref","first-page":"11158","DOI":"10.1523\/JNEUROSCI.1547-16.2016","article-title":"Ketamine: NMDA receptors and beyond","volume":"36","author":"Zorumski","year":"2016","journal-title":"J\u00a0Neurosci"},{"key":"10.1016\/j.anai.2019.01.016_bib52","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1001\/archderm.135.10.1274","article-title":"Therapy-resistant erythrodermia-related pruritus: effective treatment with ketamine hydrocholoride","volume":"135","author":"Fischer","year":"1999","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.anai.2019.01.016_bib53","doi-asserted-by":"crossref","first-page":"542","DOI":"10.2340\/00015555-2047","article-title":"Topical TrkA kinase inhibitor CT327 is an effective, novel therapy for the treatment of pruritus due to psoriasis: results from experimental studies, and efficacy and safety of CT327 in a phase 2b clinical trial in patients with psoriasis","volume":"95","author":"Roblin","year":"2015","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"10.1016\/j.anai.2019.01.016_bib54","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.cell.2014.03.064","article-title":"A\u00a0monoclonal antibody that targets a Nav1.7 channel voltage sensor for pain and itch relief","volume":"157","author":"Lee","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.anai.2019.01.016_bib55","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.neuroscience.2012.09.019","article-title":"Cross-sensitization of histamine-independent itch in mouse primary sensory neurons","volume":"226","author":"Akiyama","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.anai.2019.01.016_bib56","article-title":"PAR2 pepducin-based suppression of inflammation and itch in atopic dermatitis models","author":"Barr","year":"2018","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.anai.2019.01.016_bib57","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1146\/annurev-genet-120116-024723","article-title":"Mas-related G protein-coupled receptors and the biology of itch sensation","volume":"51","author":"Meixiong","year":"2017","journal-title":"Annu Rev Genet"},{"issue":"12","key":"10.1016\/j.anai.2019.01.016_bib58","first-page":"1384","article-title":"Association between frequency of pruritic symptoms and perceived psychological stress","volume":"145","author":"Yamamoto","year":"2009","journal-title":"Ach Dermatol"},{"issue":"2","key":"10.1016\/j.anai.2019.01.016_bib59","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2340\/00015555-2177","article-title":"Psychological interventions in the treatment of chronic itch","volume":"96","author":"Schut","year":"2016","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"10.1016\/j.anai.2019.01.016_bib60","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2340\/00015555-1039","article-title":"Notalgia paresthetica: successful treatment with exercises","volume":"91","author":"Fleischer","year":"2011","journal-title":"Acta Derm Venereol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619300857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619300857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:23:10Z","timestamp":1761052990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619300857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1081120619300857"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.01.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic itch management: therapies beyond those targeting the immune system","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.01.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}